Abstract
Background Recently developed software utilizing artificial intelligence for fast detection and triage of stroke cases has the potential to accelerate stroke care and improve patient outcomes. We performed this analysis to evaluate the performance and time-to-notification of one such software - RAPID LVO.
Methods We created a database of 151 consecutive acute stroke patients for whom CT scans were processed by the RAPID LVO software over a period of eight months. The LVO notification and time to notification of the software were collected, alongside patient information and the CTA findings.
Results RAPID LVO achieved a sensitivity of 63.6% and specificity of 85.8% for large vessel occlusion, with an average time to notification of 32.53 minutes.
Conclusions RAPID LVO has low sensitivity, moderate specificity and high time-to-notification performance. Our study data demonstrated in particular low overall sensitivity (63%) for distal occlusions (M2-3). The disparity between the observed performance and the performance reported in RAPID LVO’s FDA clearance demonstrates the importance of independent, multi-center evaluation. The gap between the performance in this study compared to published records of RAPID AI may be due to differences in imaging hardware, software implementation, connectivity or clinical definitions.
Competing Interest Statement
authors #1 and #2 are have received financial support from Viz.ai
Clinical Trial
The study is retrospective.
Funding Statement
The study was not funded.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
On 2021-01-21, delegated review of the research project was provided by members of McGill University Health Centre(MUHC), Research Ethics Board(REB), more precisely its Neurosciences and Psychiatry panel(NEUPSY). After reviewing the documents this research was approved. The Co Chair of the Neurosciences and Psychiatry panel full name is: Brigitte Paquet.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Correction of the conflict of interest.
Data Availability
1. The Imaging are fully available on the MUHC PACS database. 2. The excel spreadsheet is available as supplementary .
